|
Oct 10
|
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
|
Jul 25
|
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
|
|
Jul 10
|
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
|
|
Jun 27
|
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
|
|
May 21
|
Purple Biotech Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
|
|
Mar 28
|
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
|
|
Mar 14
|
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
|
|
Mar 5
|
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Dec 20
|
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
|
|
Dec 14
|
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
|
|
Nov 2
|
Purple Biotech Fortifies NT219 Patent Protection
|
|
Oct 3
|
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
|